Old Web
English
Sign In
Acemap
>
authorDetail
>
Johannes Nippgen
Johannes Nippgen
Medicine
Cancer
Pathology
Phases of clinical research
Cancer research
4
Papers
428
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of maintenance therapy with anti-TA-MUC1 monoclonal antibody PankoMab after chemotherapy in patients with recurrent epithelial ovarian carcinoma.
2014
Journal of Clinical Oncology
Jonathan A. Ledermann
Ingo von Broen
Frank Zimmermann
Johannes Nippgen
Steffen Goletz
Show All
Source
Cite
Save
Citations (0)
Integrin for use in the treatment of cancer
2008
Michael Weller
Ulrike Grimm
Simon Goodman
Andreas Harstrick
Stefan Krueger
Martin Picard
Johannes Nippgen
R. Stupp
Show All
Source
Cite
Save
Citations (0)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
2008
Journal of Clinical Oncology
David A. Reardon
Karen Fink
Tom Mikkelsen
Timothy F. Cloughesy
Alison ONeill
Scott R. Plotkin
Michael Glantz
Paula Ravin
Jeffrey Raizer
Keith M. Rich
David Schiff
William R. Shapiro
Susan Burdette-Radoux
Edward J. Dropcho
Sabine M. Wittemer
Johannes Nippgen
Martin Picard
L. Burt Nabors
Show All
Source
Cite
Save
Citations (428)
Thérapie spécifique utilisant des ligands d'intégrine pour traiter le cancer
2007
Simon Dr. Goodman
Martin Picard
Johannes Nippgen
Andreas Harstrick
Ulrike Grimm
Matthias Grell
R. Stupp
Michael Weller
Tom Mikkelsen
Show All
Source
Cite
Save
Citations (0)
1